Free Trial
→ Elon's next millionaires start October 24? (From Behind the Markets) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ADOIF
Adocia
C$8.87
C$8.87
C$8.87
▼
C$11.24
N/AN/A2,000 shsN/A
Adhera Therapeutics, Inc. stock logo
ATRX
Adhera Therapeutics
$0.00
$0.00
▼
$0.01
N/A12.1910,003 shs6 shs
TRSBF
3SBio
$1.90
$2.13
$1.90
▼
$4.74
N/AN/A2,350 shs260 shs
VACBF
Nykode Therapeutics AS
$0.45
$0.40
$0.32
▼
$0.45
N/AN/A1,000 shsN/A
The 10 Best High-Yield Dividend Stocks for 2026 Cover
The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ADOIF
Adocia
0.00%0.00%0.00%0.00%0.00%
Adhera Therapeutics, Inc. stock logo
ATRX
Adhera Therapeutics
0.00%0.00%0.00%0.00%0.00%
TRSBF
3SBio
0.00%-11.63%-11.63%-11.63%-48.65%
VACBF
Nykode Therapeutics AS
0.00%0.00%+6.80%+41.36%+127.10%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ADOIF
Adocia
C$8.87
C$8.87
C$8.87
▼
C$11.24
N/AN/A2,000 shsN/A
Adhera Therapeutics, Inc. stock logo
ATRX
Adhera Therapeutics
$0.00
$0.00
▼
$0.01
N/A12.1910,003 shs6 shs
TRSBF
3SBio
$1.90
$2.13
$1.90
▼
$4.74
N/AN/A2,350 shs260 shs
VACBF
Nykode Therapeutics AS
$0.45
$0.40
$0.32
▼
$0.45
N/AN/A1,000 shsN/A
The 10 Best High-Yield Dividend Stocks for 2026 Cover
The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ADOIF
Adocia
0.00%0.00%0.00%0.00%0.00%
Adhera Therapeutics, Inc. stock logo
ATRX
Adhera Therapeutics
0.00%0.00%0.00%0.00%0.00%
TRSBF
3SBio
0.00%-11.63%-11.63%-11.63%-48.65%
VACBF
Nykode Therapeutics AS
0.00%0.00%+6.80%+41.36%+127.10%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ADOIF
Adocia
0.00
N/AN/AN/A
Adhera Therapeutics, Inc. stock logo
ATRX
Adhera Therapeutics
0.00
N/AN/AN/A
TRSBF
3SBio
0.00
N/AN/AN/A
VACBF
Nykode Therapeutics AS
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ADOIF
Adocia
N/AN/AN/AN/AN/AN/A
Adhera Therapeutics, Inc. stock logo
ATRX
Adhera Therapeutics
N/AN/AN/AN/AN/AN/A
TRSBF
3SBio
N/AN/AN/AN/AN/AN/A
VACBF
Nykode Therapeutics AS
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ADOIF
Adocia
N/AN/AN/AN/AN/AN/AN/AN/AN/A
Adhera Therapeutics, Inc. stock logo
ATRX
Adhera Therapeutics
N/A-$0.83N/AN/AN/AN/AN/AN/AN/A
TRSBF
3SBio
N/AN/AN/AN/AN/AN/AN/AN/AN/A
VACBF
Nykode Therapeutics AS
N/AN/AN/AN/AN/AN/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
ADOIF
Adocia
N/AN/AN/AN/AN/A
Adhera Therapeutics, Inc. stock logo
ATRX
Adhera Therapeutics
N/AN/AN/AN/AN/A
TRSBF
3SBio
N/AN/AN/AN/AN/A
VACBF
Nykode Therapeutics AS
N/AN/AN/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
ADOIF
Adocia
N/A
Adhera Therapeutics, Inc. stock logo
ATRX
Adhera Therapeutics
N/A
TRSBF
3SBio
N/A
VACBF
Nykode Therapeutics AS
N/A

Insider Ownership

CompanyInsider Ownership
ADOIF
Adocia
N/A
Adhera Therapeutics, Inc. stock logo
ATRX
Adhera Therapeutics
28.20%
TRSBF
3SBio
N/A
VACBF
Nykode Therapeutics AS
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
ADOIF
Adocia
97N/AN/ANot Optionable
Adhera Therapeutics, Inc. stock logo
ATRX
Adhera Therapeutics
211.63 million8.35 millionNot Optionable
TRSBF
3SBio
5,411N/AN/ANot Optionable
VACBF
Nykode Therapeutics AS
171N/AN/ANot Optionable

Recent News About These Companies

Nykode Therapeutics AS (VACBF) Q4 2025 Earnings Call Transcript
February 25, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4874736-nykode-therapeutics-as-vacbf-q4-2025-earnings-call-transcript
Nykode Therapeutics AS (VACBF) Q3 2025 Earnings Call Transcript
November 24, 2025  |  seekingalpha.comhttps://seekingalpha.com/article/4847146-nykode-therapeutics-as-vacbf-q3-2025-earnings-call-transcript
Nykode Therapeutics AS (VACBF) Q2 2025 Earnings Call Highlights: From Net Loss to Profit Amid ...
August 28, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/nykode-therapeutics-vacbf-q2-2025-070225912.html
Nykode, after losing Genentech pact and laying off staff, bets future on phase 2 cancer trial
August 28, 2025  |  fiercebiotech.comF
VACBF | Nykode Therapeutics A/S Annual Cash Flow Statement - MarketWatch
July 2, 2025  |  marketwatch.comhttps://www.marketwatch.com/investing/stock/vacbf/financials/cash-flow
VACBF Nykode Therapeutics AS - Seeking Alpha
July 1, 2025  |  seekingalpha.comhttps://seekingalpha.com/symbol/VACBF
Nykode Therapeutics AS (VACBF) - Yahoo Finance
June 26, 2025  |  au.finance.yahoo.comhttps://au.finance.yahoo.com/quote/VACBF/
Nykode Therapeutics AS (VACBF) Q1 2025 Earnings Call Highlights: Strategic Streamlining and ...
May 29, 2025  |  gurufocus.comhttps://www.gurufocus.com/news/2894552/nykode-therapeutics-as-vacbf-q1-2025-earnings-call-highlights-strategic-streamlining-and-strong-financial-position-amid-revenue-challenges
Q1 2025 Nykode Therapeutics ASA Earnings Call Transcript
May 28, 2025  |  gurufocus.comhttps://www.gurufocus.com/news/2894460/q1-2025-nykode-therapeutics-asa-earnings-call-transcript
Nykode Therapeutics AS (VACBF) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ...
February 27, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/nykode-therapeutics-vacbf-q4-2024-070502959.html
Man City news: Erling Haaland investment can’t save ailing vaccine company
January 21, 2025  |  msn.comhttps://www.msn.com/en-us/money/general/man-city-news-erling-haaland-investment-can-t-save-ailing-vaccine-company/ar-AA1xwS8y
Nykode Therapeutics AS (VACBF) Q3 2024 Earnings Call Highlights: Strategic Shifts and Financial ...
November 28, 2024  |  gurufocus.comhttps://www.gurufocus.com/news/2618202/nykode-therapeutics-as-vacbf-q3-2024-earnings-call-highlights-strategic-shifts-and-financial-stability-amid-challenges
Q3 2024 Nykode Therapeutics ASA Earnings Call Transcript
November 27, 2024  |  gurufocus.comhttps://www.gurufocus.com/news/2618165/q3-2024-nykode-therapeutics-asa-earnings-call-transcript
Nykode Therapeutics And 2 More Penny Stocks Worth Watching
November 20, 2024  |  finance.yahoo.comhttps://finance.yahoo.com/news/nykode-therapeutics-2-more-penny-190532985.html
In 'surprise' termination, Genentech drops Nykode partnership for individualized cancer vaccine
November 9, 2024  |  fiercebiotech.comF
Nykode Therapeutics Announces Updates on its Inverse Vaccine Platform at PEGS Europe
November 6, 2024  |  globenewswire.comhttps://www.globenewswire.com/news-release/2024/11/06/2975868/0/en/nykode-therapeutics-announces-updates-on-its-inverse-vaccine-platform-at-pegs-europe.html
Nykode vaccine shows its worth in cervical cancer trial
October 7, 2024  |  pharmaphorum.comP
Nykode Therapeutics AS (5VB.DU)
September 17, 2024  |  finance.yahoo.comhttps://finance.yahoo.com/quote/5VB.DU/news/
Nykode Therapeutics Announces Issuance of Key Patent Covering Individualized Neoantigen Based Vaccines
August 14, 2024  |  globenewswire.comhttps://www.globenewswire.com/news-release/2024/08/14/2929767/0/en/nykode-therapeutics-announces-issuance-of-key-patent-covering-individualized-neoantigen-based-vaccines.html
Nykode Therapeutics Announces Updates on its Inverse Vaccine Platform at FOCIS 2024 Meeting
June 20, 2024  |  globenewswire.comhttps://www.globenewswire.com/news-release/2024/06/20/2901364/0/en/nykode-therapeutics-announces-updates-on-its-inverse-vaccine-platform-at-focis-2024-meeting.html

Media Sentiment Over Time

Adocia OTCMKTS:ADOIF

C$8.87 0.00 (0.00%)
As of 05/12/2023

Adocia SA, a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary BioChaperone technological platform provides molecular delivery of therapeutic proteins. The company's clinical product pipeline includes insulin formulations, such as BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid insulin lispro; BioChaperone Combo, a combination of acting insulin glargine and rapid-acting insulin lispro; BioChaperone LisPram, a combination of prandial insulin with pramlintide; and BioChaperone Glucagon, an aqueous formulation of human glucagon for the treatment of hypoglycemia, as well as M1Pram, a metabolite of insulin glargine and pramlintide. Its preclinical pipeline includes products for the treatment of diabetes and obesity comprising AdoShell Islets, an implant containing islets of Langerhans; AdOral Sema, an oral delivery of semaglutide; and BioChaperone GluExe, a combination of glucagon and exenatide. The company has a strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd. to develop and commercialize BioChaperone Lispro and BioChaperone Combo in China and other Asian and Middle Eastern territories. Adocia SA was incorporated in 2005 and is headquartered in Lyon, France.

Adhera Therapeutics stock logo

Adhera Therapeutics OTCMKTS:ATRX

Adhera Therapeutics, Inc., a biotech company, focuses on the discovery, development, and commercialization of small molecule drugs. The company is developing MLR-1019 for the treatment of Parkinson's disease; and MLR -1023 to treat Type 1 diabetes. The company was formerly known as Marina Biotech, Inc. and changed its name to Adhera Therapeutics, Inc. in October 2018. Adhera Therapeutics, Inc. is based in Baton Rouge, Louisiana.

3SBio OTCMKTS:TRSBF

$1.90 0.00 (0.00%)
As of 10/12/2026 09:52 AM Eastern

3SBio Inc., an investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; Cipterbin, an anti-HER2 monoclonal antibody for the treatment of HER2-positive metastatic breast cancer; TNF, pre-filled aqueous injection solution. It also offers YISAIPU, the receptor fusion tumor necrosis factor inhibitor; Mandi-minoxidil tincture, an OTC external medicine for treating hair loss; EPIAO and SEPO, an erythropoietin injection; SPARIN, an injectable low-molecular-weight heparin calcium. In addition, the company provides MN709 Minoxidil Foam and Nalfuraphine hydrochloride tablets. Further, it provides trading, project management and consultation, technology, sports, financial, investment advisory, as well as manufactures medical devices; and offers agricultural services. The company has collaboration agreements with companies, such as Toray. 3SBio Inc. was founded in 1993 and is headquartered in Shenyang, the People's Republic of China.

Nykode Therapeutics AS OTCMKTS:VACBF

$0.45 0.00 (0.00%)
As of 10/9/2026

Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies. The company develops vaccines for the treatment cancer and infectious diseases. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is in phase I/IIa clinical trial for the treatment of ,melanoma, lung, bladder, renal, head, and neck cancer; VB10.16, a therapeutic vaccine, which in phase II clinical trial for the treatment of human papilloma virus 16 induced malignancies, such as cervical cancer; and VB10. COV2, a COVID-19 vaccine candidate covers new SARS-CoV-2 variants. The company has collaboration agreements with Roche, Genentech, MSD, and Nektar Therapeutics; Adaptive Biotechnologies for T cell vaccine development; and research agreement with Regeneron. Nykode Therapeutics AS was founded in 2006 and is based in Oslo, Norway.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas